000176937 001__ 176937
000176937 005__ 20240229133725.0
000176937 0247_ $$2doi$$a10.1186/s13550-021-00846-y
000176937 0247_ $$2pmid$$apmid:34628525
000176937 0247_ $$2altmetric$$aaltmetric:114928976
000176937 037__ $$aDKFZ-2021-02177
000176937 041__ $$aEnglish
000176937 082__ $$a610
000176937 1001_ $$0P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aSachpekidis, Christos$$b0$$eFirst author$$udkfz
000176937 245__ $$aThe prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs).
000176937 260__ $$aHeidelberg$$bSpringer$$c2021
000176937 3367_ $$2DRIVER$$aarticle
000176937 3367_ $$2DataCite$$aOutput Types/Journal article
000176937 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634038908_10607
000176937 3367_ $$2BibTeX$$aARTICLE
000176937 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000176937 3367_ $$00$$2EndNote$$aJournal Article
000176937 500__ $$a#EA:E060#LA:E060#
000176937 520__ $$a[18F]FDG PET/CT is the elective imaging modality for treatment monitoring in multiple myeloma (MM). However, MM is a heterogeneous disease from an imaging point of view, raising challenges in interpretation of PET/CT. We herein investigated the prognostic role of the novel Italian Myeloma criteria for PET Use (IMPeTUs) in MM patients undergoing high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT).Forty-seven patients with newly diagnosed MM underwent [18F]FDG PET/CT before commencement of treatment (baseline PET/CT). Thirty-four of them (72.3%) were also examined after completion of ASCT (follow-up PET/CT). PET/CT analysis was based on the IMPeTUs criteria, which take into consideration-among others-the metabolic state of the bone marrow based on the 5-point Deauville score (DS), the number and metabolic state of focal [18F]FDG-avid lesions, as well as the presence of paramedullary disease (PMD) and extramedullary disease (EMD). We analyzed whether parameters from IMPeTUs correlate with clinically relevant parameters and patients' outcome, as assessed by progression-free survival (PFS).Median follow-up from baseline and follow-up PET/CT were 85.1 months and 76.7 months, respectively. The number of focal, [18F]FDG-avid lesions significantly correlated with the bone marrow infiltration rate and the R-ISS stage, while the presence of PMD was associated with LDH. After univariate survival analysis, the number of focal, [18F]FDG-avid lesions both before and after therapy as well as the presence of PMD and EMD before therapy adversely affected PFS. Multivariate survival analysis for baseline parameters confirmed that the number of focal, [18F]FDG-avid lesions and the presence of EMD are associated with adverse prognosis, irrespective of the ISS stage and/or the presence of high-risk cytogenetic abnormalities. The 5-point DS of [18F]FDG uptake in reference bone marrow and focal lesions showed a significant decrease as response to treatment, but it did not affect PFS.Several parameters utilized in IMPeTUs predict PFS in MM patients, suggesting the potentially significant role of the new criteria in patient stratification and response assessment. Additional studies are warranted for the further evaluation of IMPeTUs in the direction of establishment of robust cut-off values with a prognostic significance in the disease.
000176937 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000176937 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000176937 650_7 $$2Other$$aInterpretation criteria
000176937 650_7 $$2Other$$aItalian Myeloma criteria for PET Use (IMPeTUs)
000176937 650_7 $$2Other$$aMultiple myeloma
000176937 650_7 $$2Other$$a[18F]FDG PET/CT
000176937 7001_ $$aMerz, Maximilian$$b1
000176937 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, Marc-Steffen$$b2$$udkfz
000176937 7001_ $$aBertsch, Uta$$b3
000176937 7001_ $$0P:(DE-He78)7dc85735e114a4ace658ba1450a2cca6$$aWeru, Vivienn$$b4$$udkfz
000176937 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b5$$udkfz
000176937 7001_ $$aJauch, Anna$$b6
000176937 7001_ $$aGoldschmidt, Hartmut$$b7
000176937 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b8$$eLast author$$udkfz
000176937 773__ $$0PERI:(DE-600)2619892-7$$a10.1186/s13550-021-00846-y$$gVol. 11, no. 1, p. 100$$n1$$p100$$tEJNMMI Research$$v11$$x2191-219X$$y2021
000176937 909CO $$ooai:inrepo02.dkfz.de:176937$$pVDB
000176937 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000176937 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000176937 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7dc85735e114a4ace658ba1450a2cca6$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000176937 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000176937 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000176937 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000176937 9141_ $$y2021
000176937 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEJNMMI RES : 2019$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-02-04
000176937 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-04
000176937 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-04
000176937 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000176937 9201_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x1
000176937 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x2
000176937 980__ $$ajournal
000176937 980__ $$aVDB
000176937 980__ $$aI:(DE-He78)E060-20160331
000176937 980__ $$aI:(DE-He78)A360-20160331
000176937 980__ $$aI:(DE-He78)C060-20160331
000176937 980__ $$aUNRESTRICTED